ANZCTR search results

Sleep is a physiological requirement which impacts the function of every cell, tissue and organ. Sleep is also pivotal in maintaining psychological wellbeing. Poor sleep quality and reduced sleep quantity have tangible effects on mental and physical wellbeing. Sleep complaints are prevalent amongst caregivers of people living with dementia and have been associated with increased risk of institutionalisation of the person they are caring for, an increased sense of burden and poorer psychological health. This study will be an acceptability and feasibility project which will support the development and implementation of a sleep program for caregivers of people living with dementia. The project aims to develop an intervention which will help equip caregivers with the knowledge and skills to improve their sleep. The sleep intervention will be delivered once a week for four weeks, with sleep and psychological wellbeing being assessed before and after the intervention. We hypothesize that the sleep intervention will improve carers sleep, reduce stress, anxiety and burden, and improve their overall psychological wellbeing. Sleep interventions are an easily implementable, cost-effective means of maintaining and improving caregivers physical and mental wellbeing. By ensuring we optimise the health of the caregiver, we allow them to thrive in their caregiving capacity which has a positive impact on both the caregiver and the person living with dementia.

This trial aims to determine the feasibility and acceptability of a digital educational physical activity program in children who have survived cancer, and to evaluate its impact on physical activity levels, cardiovascular fitness, quality of life, and sugar-sweetened beverage intake in these children. Who is it for? You may be eligible for this study if you are aged 8-13 years, and have completed cancer treatment at least 12 months ago or are in the maintenance phase of leukaemia chemotherapy. Study details Participants will be given a tablet with an installed app that delivers a physical activity education program over 12 weeks through ten 60-minute interactive modules. Participants will also be provided with an activity tracker to wear for the duration of the study. A number of questionnaires will be given before and after the study to assess feasibility and acceptability of the program, and the level of fitness will be assessed at baseline, after the 12 weeks and at 3-month follow-up using the 6-minute walk test, where the participant walks as fast as they can in a 6-minute period. It is hoped that this study may help to foster healthy behaviours and improve physical fitness in childhood cancer survivors.

The CellAED device is a novel automated external defibrillator (AED) or commonly referred to as a defibrillator. The purpose of this study is to test this new AED and demonstrate its ability to deliver an appropriate shock to help restore a patient in cardiac arrest to a normal heart rhythm. The hypothesis is that the CellAED will be able to terminate arrhythmias (VT or VF) in a patient to allow the heart to restore a Normal Sinus Rhythm. Once consented, patients will be scheduled for the cardiac procedure. Patients will have the CellAED applied to their chest prior to the procedure starting. In addition, as a safety precaution, patients will have a traditional defibrillator applied to their chest as a rescue therapy device should the first shock delivered by the CellAED fail to revert the patient to normal sinus rhythm. During the procedure, if patient experiences a shockable rhythm (VT/VF) the cardiologist will activate the CellAED (in accordance with instructions in the Instructions for Use). This will be performed up to a maximum of one (1) time. The rhythm will be immediately assessed and if required, back up defibrillation will be delivered utilizing the standard defibrillator available on site.

Our study is designed to evalute the patency rates and clinical outcomes in patients using an instrumented radial artery for coronary artery bypass grafting. An instrumented radial artery is one where an invasive coronary angiogram has been performed by inserting wires and catheters through the radial artery in to the heart. It is possible that this procedure may injure the radial artery and make it less useful as a bypass graft. In recent years, there has been an increasing preference for using arteries as bypass grafts in coronary artery bypass grafting, and invasive coronary angiograms are now routinely performed via the radial artery. Therefore, there is an increasingly common scenario of deciding whether the instrumented radial artery should be used as a bypass graft, and there is very little evidence to guide this decision. Our study will retrospectively identify patients who underwent CABG with instrumented radial arteries. We will then compare their outcomes to patients who did not have an instrumented radial artery used as a graft. Additionally, a subset of patients will undergo CT coronary angiograms. CT coronary angiograms look for narrowings in the blood vessels that supply the heart, without the need for catheters to be inserted. We will compare the narrowings / blockages in the instrumented radial artery with non-instrumented radial arteries, internal mammary arteries and saphenous vein grafts to determine whether instrumented radial arteries become blocked more quickly. Our hypothesis is that instrumented radial arteries have lower patency rates, and therefore higher rates of graft failure, then non-instrumented radial arteries, when used for coronary artery bypass grafting

This study aims to determine whether a personalised exercise program has any protective effects on the gut microbiota in breast cancer survivors, which may have follow-on effects for overall health and immune response in these patients. Who is it for? You may be eligible for this study if you are aged between 18-80, you are a Stage I-III breast cancer survivor who is 3-12 months post completion of your adjuvant treatment (hormone therapy and Herceptin may be continuing), you have undergone curative surgery and/or chemotherapy and/or radiotherapy and you are currently completing less than the recommended physical activity guidelines (150 minutes of moderate intensity structured activity per week). Study details Participants who enroll in this study will be randomly allocated by chance (similar to flipping a coin) to either the intervention or the control treatment. Participants allocated to the intervention treatment will be prescribed an individualised exercise program to be completed for 12 weeks. The exercise program will involve a combination of aerobic exercise (such as jogging/swimming/cycling) and upper and lower limb resistance exercises using a thera-band. Each week, participants in the intervention group will also receive a 10–20-minute telephone call with a member of the research team to discuss their progress and any concerns they may have about the exercise program. Participants allocated to the control treatment will be asked to maintain their current physical activity levels throughout the 12-week intervention. No telephone support will be provided to the control participants throughout the intervention. At the completion of the intervention, after follow-up testing, the control participants will be offered an opportunity to receive an individualised exercise program. All participants in this study will undergo a baseline (pre-intervention) and follow-up assessment to determine their fitness levels, and will be asked to provide stool and blood samples to determine their levels of inflammation and the characteristics of their gut microbiome. All participants will be asked to wear an activity tracker to monitor their physical activity daily for the 12 weeks of the study. It is hoped this research will demonstrate that moderate physical exercise has a positive effect on the gut microbiota of cancer survivors and this may also reduce systemic inflammation in these patients.

This is a single centre, double-blind, randomised, vehicle-controlled study designed to assess the safety, tolerability, and pharmacokinetics of GDD3898 Topical Gel following twice daily application for 14 days in healthy volunteers. 16 subjects will be enrolled in 2 cohorts. Cohort 1 will comprise of 8 subjects randomised in a 3: to 1 ratio to be treated with either GDD3898 Topical Gel (1.75%) BID or vehicle gel BID on the anterior and posterior sections one forearm (540 cm2) for 14 days.. Cohort 2 will comprise of 8 subjects randomised in a 3 to :1 ratio to be treated with either GDD3898 Topical Gel (1.75%) BID or vehicle gel BID on the anterior and posterior sections of one arm, both forearm and upper arm (1260 cm2), for 14 days. Serial blood pharmacokinetic samples will be collected. After discharge from the CRU on Day 16, all subjects will have a follow-up telephone contact 7 days after last application of study drug.

This trial aims to investigate the efficacy of oral pyridostigmine, a medication currently used to treat Myasthenia Gravis, in the treatment of acute colonic pseudo-obstruction (ACPO). Acute colonic pseudo-obstruction occurs when the large intestine becomes dilated in the absence of downstream mechanical obstruction, and often occurs in the setting of hospitalized patients who are non-mobile, and/or are on significant amounts of opioid medications. Current treatment options for ACPO include the use of medications such as intravenous neostigmine, which is effective but requires cardiac monitoring due to the risk of cardiac arrhythmias, endoscopic decompression, or surgery. A recently published case series has suggested that oral pyridostigmine is effective in treating patients with ACPO, without the need for cardiac monitoring, unlike neostigmine. However, strong evidence in this field is still lacking, which this study aims to help address.

This study is investigating how different formats of information provision on breast density affect women’s screening intentions, psychological outcomes and knowledge of breast density. Who is it for? You may be eligible for this trial if you are female, aged 40-74 years, live outside Western Australia and have no prior history of breast cancer or ductal carcinoma in situ. Study details Participants in this study will complete an online questionnaire and during which will be presented with a hypothetical scenario of undergoing a routine screening mammogram and receiving the results. Participants will be randomised to receive control information (screening mammogram result without the breast density messaging) or one of two versions of the intervention with breast density information via notification messaging. Participants will then be asked to complete questions in response to the information they have received. It is hoped this study will inform researchers of how different formats of information on breast density impact women's screening intentions and psychological outcomes.

When intravenous (IV) catheters stop working the medication meant to be delivered into the bloodstream pools into the tissue; known as an extravasation injury (extra=out of; vas = vessel) - a serious cause of harm that can result in permanent scarring. They are especially common in paediatrics as children have small vessels, and can't always tell us when their IV starts to hurt. An effective way to reduce these injuries is to ensure that the right IV is inserted in the right place, at the beginning of treatment.There are new international guidelines on the selection and insertion of IVs in paediatrics; known as the Michigan Appropriateness Guide for Intravenous Catheters in paediatrics (miniMAGIC). They provide recommendations on IV catheter choices (e.g., smaller vs larger vessels), and where to insert them (e.g., foot vs forearm). Within this project our team will tailor and implement miniMAGIC in sequential blocks across the Queensland Children’s Hospital. We will create resources to ensure miniMAGIC is practical and easy to use in Australian healthcare, and then measure how well it performed to improve IV choice and reduce extravasations.

A multi-site prospective study to implement and evaluate the feasibility of a Pharmacogenetics Screening Program for 5-fluorouracil [5-FU], capecitabine and irinotecan chemotherapies for patients with cancer Who is it for? You may be eligible to join this study if you are aged 18 and above, have been diagnosed with cancer and will receive fluorouracil [5-FU], capecitabine and/or irinotecan chemotherapy for the first time. Study details All participants in this study will receive a genetic screening for DPYD gene test if commencing on 5-FU or capecitabine and/or screening for UGT1A1 gene if commencing on irinotecan anticancer treatment, 7 to 10 days before starting chemotherapy. It is the responsibility and choice of the treating clinician to implement/not implement dosing recommendations based on genetic tests and to manage all aspects of cancer treatment. The feasibility of operating a Pharmacogenetics Screening Program will be assessed using recruitment data from study databases and patient and clinician surveys. Participants will also be followed for up to 12 months to assess toxicities and 24 months to assess treatment response and status. This research will contribute to improve health outcomes for patients with cancer in terms of safety and survival in particular patients who carry altered/deficient genes; dose individualisation prior to administration to 5-FU or capecitabine and/or irinotecan will assist with better tolerance to treatment and hospitalisations (given better toxicity management).